A new study published in Molecular Systems Biology by Charlie George Barker, Sumana Sharma, Evangelia Petsalaki and colleagues at the European Molecular Biology Laboratory and collaborating institutions across Europe offers one of the most detailed maps yet of how this resistance is built. The team focused on ARID1A, a component of the SWI/SNF chromatin remodeling complex that is mutated in approximately 11.5 percent of melanomas. Unlike the hotspot mutations that activate BRAF, ARID1A mutations are scattered across the gene, a pattern typical of tumor suppressors whose loss confers a survival advantage in many different ways. Previous genome-wide CRISPR screens had already flagged ARID1A loss as a driver of resistance to MAPK pathway inhibitors, but the precise circuitry behind that resistance remained obscure.

To resolve it, the researchers engineered a drug-resistant version of the A375 melanoma cell line, a BRAF V600E model that is normally exquisitely sensitive to BRAF and MEK inhibitors, by knocking out ARID1A. They then treated both the parental and knockout lines with vemurafenib, trametinib, or the combination, harvesting cells after six hours, a time point chosen to capture the earliest adaptive signaling responses before cell death begins. From these samples they generated an unusually rich dataset: mass spectrometry quantified 8,139 proteins and 3,207 phosphosites, while RNA sequencing measured the expression of 14,376 genes. They supplemented this with functional kinomics using PamChip peptide microarrays, which measure the actual enzymatic activity of dozens of kinases in cell lysates, and with Luminex-based phosphoprotein assays to confirm that the drugs were genuinely suppressing their targets.

The analytical challenge was to make sense of four orthogonal data layers simultaneously. The team’s solution combined two computational tools. First, they applied multi-omics factor analysis, or MOFA, an unsupervised matrix factorization method that identifies latent factors explaining variation across all data modalities at once. This revealed three dominant sources of variation: two factors capturing adaptive responses to drug treatment, and a third reflecting the sustained reprogramming caused by ARID1A loss. Second, they fed the factor loadings into phuEGO, a network propagation method that places the most extreme genes and phosphosites into their functional interaction context, producing minimal signaling networks for each factor. By merging positive and negative weights, the approach generated upregulated and downregulated network modules that capture the opposing molecular programs at play in drug response and resistance.

The first factor revealed changes that occurred regardless of which drug was used, pointing to mechanisms common to all MAPK inhibition. The most striking finding was the coordinated decrease of negative feedback regulators of the pathway, including the DUSP phosphatases DUSP1, DUSP2 and DUSP4, along with SPRY1/2/4 and SPRED1/2. These molecules normally act as brakes on receptor tyrosine kinase and MAPK signaling, terminating signals after they fire. When their abundance drops, the brakes come off, growth factor signaling intensifies, and the effect of the inhibitors is blunted. At the same time, the functional kinomics data showed activation of several receptor-associated kinases, including PRKD1, FYN and IGF1R, even though the abundance of their mRNAs and proteins barely changed. This dissociation between expression and activity underscores why measuring phosphorylation and kinase function, not just gene expression, is essential for understanding drug response.

The second factor isolated changes specific to combination therapy, and here the phosphoproteomics told an unexpected story. The team detected altered phosphorylation on a series of DNA repair proteins. TP53BP1, which promotes non-homologous end joining of double-strand DNA breaks, was heavily phosphorylated on serine 1101, a site associated with ionizing radiation damage, while losing phosphorylation at several other residues. RIF1, a key TP53BP1 regulator, was modulated at a site close to a known inhibitory phosphorylation mark, and ULK1 serine 556, an ATM-dependent autophagy trigger, was strongly upregulated. Enrichment analysis of the downregulated network highlighted terms related to ATM-mediated repair protein phosphorylation and recruitment of repair proteins to double-strand breaks, alongside suppressed immune signaling through TNF-alpha, interferons and interleukins. Intriguingly, in this particular cell line the combination therapy did not kill more cells than vemurafenib alone, suggesting these DNA damage signatures may mark cellular stress responses rather than enhanced therapeutic efficacy.

The third factor, tied to ARID1A loss, produced the study’s most consequential insights. Although the knockout cells mounted transcriptional and proteomic drug responses that correlated strongly with those of parental cells, with transcriptomic correlations of 0.91 to 0.93, their signaling behavior diverged dramatically. ARID1A knockout cells sustained MAPK1/3 and JNK activity after treatment, indicating the drugs no longer fully silenced these pathways. The researchers traced this to a fundamentally altered baseline state. The knockout cells showed elevated abundance of several receptor tyrosine kinases, including EGFR and ROS1, along with integrins and CD44. Flow cytometry confirmed a drastic increase in EGFR on the cell surface, consistent with impaired receptor endocytosis in resistant melanoma cells. Elevated membrane receptors can sustain chronic signaling rather than transient, ligand-dependent pulses, providing a persistent growth signal that survives MAPK blockade.

Using random walk network propagation and maximum-flow analysis, the team showed that signals from EGFR and ROS1 converge on the transcription factor JUN through the adaptor proteins FYN, PRKD1, PTPN6 and NCK1. In parental cells, drug treatment activates PRKD1, which suppresses the JNK/c-Jun axis linked to apoptosis in BRAF-mutant melanoma. In ARID1A knockout cells, this regulatory logic is inverted: PRKD1 activation is suppressed, JNK inhibition is relieved, and JUN activity rises, a known driver of BRAF inhibitor resistance. The predictive power of the network approach was validated experimentally. When the researchers deleted EGFR using two independent guide RNAs, the drug-resistant phenotype of the knockout cells was abolished, and cell death exceeded even that of parental cells under combination therapy. Ephrin receptor signaling, also elevated in the knockout cells, emerged as an additional resistance route through NCK1 and related adaptors.

The study also connected ARID1A loss to immune evasion, with implications for immunotherapy. The knockout cells showed reduced activity of the RFX5, RFXAP, RFXANK and NFYC transcription factors, which drive MHC class II gene expression, and correspondingly reduced surface levels of HLA-DQ and HLA-DR. Analysis of 472 melanoma patients from The Cancer Genome Atlas confirmed the pattern: the 80 patients with ARID1A mutations or deletions had significantly lower predicted activity of these MHC regulators and elevated collagen and laminin expression, suggesting extracellular matrix remodeling that could physically impede T-cell infiltration. Together, the findings position PRKD1, JUN and NCK1 as key resistance nodes and highlight a sobering lesson about redundancy: with multiple receptors, including EGFR, ROS1 and FGFR1, feeding into rewired signaling, targeting any single protein is unlikely to succeed. Instead, the study’s integrative framework, which disentangles drug responses from baseline reprogramming and prioritizes experimentally testable vulnerabilities, points toward combination strategies aimed at JUN or immune pathway restoration, offering a systems-level blueprint for outmaneuvering one of cancer’s most adaptable escape artists.

Subject of Research: Multi-omics analysis of ARID1A-dependent resistance to BRAF and MEK inhibitor therapy in melanoma

Article Title: Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms

Article References: Barker, C. G., Sharma, S., Santos, A. M., Nikolakopoulos, K.-S., Velentzas, A. D., Tormo-Garcia, C., Sharma, A., Völlmy, F. I., Minia, A., Pliaka, V., Clarke, J., Altelaar, M., Wright, G. J., Alexopoulos, L. G., Stravopodis, D. J., & Petsalaki, E. (2026). Integrative multi-omics defines melanoma drug response networks and ARID1A-dependent resistance mechanisms. Molecular Systems Biology, 22(5), 685-711. https://doi.org/10.1038/s44320-025-00183-5

Image Credits: AI Generated

DOI: 10.1038/s44320-025-00183-5

Keywords: melanoma, ARID1A, drug resistance, BRAF inhibitors, MEK inhibitors, MAPK signaling, multi-omics, phosphoproteomics, EGFR, JUN, immune evasion, network biology

Extracellular vesicles, often called EVs, are lipid-enclosed nanoparticles shed by virtually every cell type in the body. Once dismissed as cellular garbage disposal, they are now recognized as a genuine intercellular communication system: they ferry proteins, lipids and nucleic acids between cells, and their cargo changes with physiological state. Exercise is a particularly powerful modulator of this cargo. Previous work has shown that the blood of trained individuals contains circulating exosomes with distinct microRNA profiles compared with sedentary controls, and that exercise-induced vesicles can protect the heart against ischemia-reperfusion injury and influence metabolic disease. What remained unknown, and what the new study set out to resolve, is precisely how the microRNA payload of exercise-primed vesicles is decoded by recipient cells in distant tissues, and which downstream genes translate that message into a measurable health benefit.

The researchers chose articular cartilage as their model tissue for good reason. Cartilage is avascular, poorly innervated and notoriously resistant to self-repair, and its degeneration underlies osteoarthritis, one of the most burdensome age-related diseases worldwide. The Global Burden of Disease Study 2021 projects that the number of people living with osteoarthritis will continue climbing toward 2050, and clinical guidelines already recommend exercise as first-line, non-surgical management. Yet cartilage cells, or chondrocytes, sit embedded in a dense matrix far from any blood vessel, making it biologically puzzling that a systemic intervention like jogging could improve their health at all. The answer, the study suggests, travels in vesicles small enough to cross the blood-joint barrier.

To find that answer, the team combined human intervention data with computational network biology. In a three-month aerobic exercise program involving older adults, the researchers isolated extracellular vesicles from participants’ plasma before and after the intervention and profiled their small RNA content by sequencing. An acute bout of exercise significantly altered sixteen vesicular microRNAs, and pathway analysis showed that these exercise-sensitive microRNAs predominantly targeted genes involved in cell-matrix adhesion, the molecular anchoring system by which chondrocytes sense and respond to their surrounding scaffold. Rather than testing each microRNA one by one, the team then used network propagation, a computational technique that simulates how a perturbation spreads through a tissue-specific gene interaction network, to predict the cumulative downstream effect of the altered microRNA cocktail on cartilage cells.

The network analysis delivered a strikingly clear verdict: the exercise-primed microRNA payload converged on pathways of cellular aging, with the microRNA-29 family emerging as the dominant regulator of the effect. This prediction was not merely statistical. When the researchers performed an in silico knockout of microRNA-29, the health-promoting signature of the exercise-primed vesicles was substantially attenuated, pinpointing this single microRNA family as a key node in the cartilage-aging regulatory network. The microRNA-29 family has an established track record in regenerative biology, with prior studies implicating it in the regulation of collagen expression, fibrosis and synovial inflammation, but its role as the exercise-responsive messenger that reprograms aged chondrocytes had not previously been appreciated.

The mechanistic core of the study concerns a gene with an almost legendary reputation in aging research: KL, which encodes the protein α-Klotho, named after the Greek Fate who spins the thread of life. The team’s earlier work had shown that age-related stiffening of the cartilage matrix epigenetically silences α-Klotho in chondrocytes through hypermethylation of the KL promoter, compromising cell integrity and pushing the cells toward a degenerative phenotype. In the new experiments, chondrocytes cultured on stiff, aged-like substrates recapitulated this pathological state, with altered cell morphology, compromised integrity and a hypermethylated KL promoter. When the researchers treated these cells with exercise-primed extracellular vesicles from the human participants, the vesicles epigenetically de-repressed KL, partially reversing the promoter hypermethylation, restoring α-Klotho expression and driving the chondrocytes back toward a more youthful, anabolic phenotype.

Causality was tested in two complementary ways. First, the researchers engineered extracellular vesicles to be enriched with microRNA-29 and showed that these synthetic packages reproduced the anabolic effects of the natural exercise-primed vesicles in aged human chondrocytes, and that this benefit depended on α-Klotho, confirming the KL gene as the functional target. MicroRNA-29 mimics also reduced the expression of Itgb1, a gene encoding an integrin subunit that was upregulated in chondrocytes on stiff substrates and identified among the leading-edge targets of the exercise-sensitive microRNAs. Second, and most importantly for translational relevance, the team injected exercise-primed extracellular vesicles directly into the knee joints of aged mice. The intra-articular administration mitigated age-related cartilage degeneration in the animals, demonstrating that the vesicle-mediated signal is not an artifact of cell culture but a physiologically meaningful intervention in a living, aging joint.

The implications ripple outward in several directions. For exercise science, the study provides the most complete mechanistic chain yet linking a behavioral intervention to epigenetic remodeling in a distal tissue: exercise alters circulating vesicular microRNA cargo, microRNA-29 de-represses KL, and α-Klotho restores chondrocyte health. For regenerative medicine, it suggests that extracellular vesicles could be harvested, engineered or pharmacologically primed to deliver microRNA-29 to damaged joints, potentially offering a disease-modifying therapy for osteoarthritis, a condition currently managed largely with pain relief and, eventually, joint replacement. The engineering approach also sidesteps some safety concerns associated with viral gene therapy, since vesicles are natural delivery vehicles, although the authors’ demonstration that the benefit is only partially dependent on α-Klotho hints that additional, still-unmapped pathways contribute to the overall effect.

Important caveats remain before microRNA-29-enriched vesicles reach the clinic. The human component of the study demonstrated that exercise raises vesicular microRNA-29 relative to each participant’s own baseline, but the therapeutic injections were performed in mice, and the dose, frequency and long-term safety of intra-articular vesicle therapy in humans are unknown. The network models, while powerful, are computational predictions that require continued experimental validation, and the heterogeneity of osteoarthritis, which includes post-traumatic as well as age-related forms, means that the microRNA-29-Klotho axis may not benefit every patient equally; indeed, the disease-enrichment analysis in the study pointed most strongly at primary, age-related knee osteoarthritis as the relevant clinical target. Still, the study marks a conceptual shift: exercise is revealed not merely as mechanical conditioning of load-bearing tissue but as a systemic signaling event, packaged into nanoparticles, written in microRNA, and read by aging cells as an instruction to switch a longevity gene back on. In that light, every aerobic workout becomes a dispatch of molecular medicine, and the challenge ahead is learning to bottle it.

Subject of Research: Exercise-primed extracellular vesicles enriched in microRNA-29 restore aged chondrocyte health through epigenetic derepression of the KL gene encoding α-Klotho

Article Title: Exercise enhances aged chondrocyte health through microRNA-29-enriched extracellular vesicles

Article References: Iijima, H., Dave, K. M., Wang, K., Khay, A. M., D’Amico, E., Tang, W.-Y., Rogers, R. J., Jakicic, J. M., & Ambrosio, F. (2026). Exercise enhances aged chondrocyte health through microRNA-29-enriched extracellular vesicles. Nature Aging. https://doi.org/10.1038/s43587-026-01225-9

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01225-9

Keywords: extracellular vesicles, microRNA-29, exercise, chondrocytes, cartilage, α-Klotho, KL gene, epigenetics, osteoarthritis, aging, network biology, regenerative medicine